Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

The South Korean office of the Danish pharmaceutical company Novo Nordisk recently requested the local authorities to permit ...

The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug with fewer ...